ORGS
Orgenesis Inc. Common StockORGS
ORGS
Delisted
ORGS was delisted on the 18th of October, 2024.
About: Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
Employees: 146
Financial journalist opinion
Neutral
Accesswire
2 months ago
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquisition of certain Neurocords LLC's ("Neurocords") assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI).
Neutral
Accesswire
4 months ago
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Funding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that it has concluded an agreement for an equity line of credit of up to $5 million from Williamsburg Venture Holdings, LLC, a Nevada-based family office.
Neutral
GlobeNewsWire
9 months ago
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study
Neutral
GlobeNewsWire
9 months ago
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture
Neutral
GlobeNewsWire
1 year ago
Orgenesis Provides Business Update for the First Quarter of 2024
Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera
Neutral
GlobeNewsWire
1 year ago
Orgenesis Provides Year End Business Update
M ajor transformation underway commencing with recent acquisition reasserting full ownership and control over Octomera
Neutral
GlobeNewsWire
1 year ago
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis' therapeutic programs and its suite of product development and GMP cell processing services. The collaboration's goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
Neutral
GlobeNewsWire
1 year ago
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe. The conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in Barcelona from March 19th to 21st, 2024.
Neutral
GlobeNewsWire
1 year ago
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that the Company has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project focused on manufacturing, loading, analytical methods and quality control of therapeutic exosomes. Consortium members include: Orgenesis, Cilyx, CMMI, convExYO, EXO Biologics, ExoXpert, Genflow Biosciences, LiveDrop, ULB, UMONS and Xomexbio. This grant is the second such project awarded to an Orgenesis consortium by the Walloon Government partnership, ATMP-Partenariat d'Innovation Technologique (ATMP-PIT), in collaboration with BioWin, the health cluster of Wallonia, and the Public service of Wallonia.
Neutral
GlobeNewsWire
1 year ago
Orgenesis Inc. Announces $2.3 Million Private Placement
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. The warrants are exercisable immediately and expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.
Charts implemented using Lightweight Charts™